↓ Skip to main content

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

Overview of attention for article published in Clinical Cancer Research, December 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
3 news outlets
twitter
7 tweeters

Citations

dimensions_citation
63 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Published in
Clinical Cancer Research, December 2019
DOI 10.1158/1078-0432.ccr-19-2177
Pubmed ID
Authors

Darren R. Hargrave, Eric Bouffet, Uri Tabori, Alberto Broniscer, Kenneth J. Cohen, Jordan R. Hansford, Birgit Geoerger, Pooja Hingorani, Ira J. Dunkel, Mark W. Russo, Lillian Tseng, Kohinoor Dasgupta, Eduard Gasal, James A. Whitlock, Mark W. Kieran

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 14%
Student > Ph. D. Student 6 12%
Student > Doctoral Student 5 10%
Student > Bachelor 3 6%
Other 3 6%
Other 7 14%
Unknown 20 39%
Readers by discipline Count As %
Medicine and Dentistry 15 29%
Biochemistry, Genetics and Molecular Biology 3 6%
Agricultural and Biological Sciences 3 6%
Neuroscience 3 6%
Engineering 2 4%
Other 5 10%
Unknown 20 39%

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2022.
All research outputs
#1,275,831
of 21,396,316 outputs
Outputs from Clinical Cancer Research
#919
of 12,192 outputs
Outputs of similar age
#39,588
of 431,889 outputs
Outputs of similar age from Clinical Cancer Research
#39
of 200 outputs
Altmetric has tracked 21,396,316 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,192 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 200 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.